Document is current
Any future updates will be listed below
-
Authors
-
Funding
Funding for this research was provided by:
Commonwealth of Pennsylvania Department of Health - Tobacco Settlement Act (410008337)
National Institutes of Health (T32 HG009495, P30 DA046345)
- License Information
-
More Information
Article History
Received: 26 August 2021
Accepted: 30 June 2022
First Online: 15 July 2022
Declarations
:
: Dr. Kranzler is a member of an advisory boards for Dicerna Pharmaceuticals, Sophrosyne Pharmaceuticals, and Enthion Pharmaceuticals; a consultant for Sobrera Pharmaceuticals; a recipient from Alkermes of funds and study medication for investigator-initiated research; a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which was supported in the last 3 years by Alkermes, Dicerna, Ethypharm, Lundbeck, Mitsubishi, and Otsuka; and holds U.S. Patent 10,900,082: Genotype-guided Dosing of Opioid Receptor Agonists, 26 Jan. 2021. The other authors have no disclosures to make.
